Table 1.

Clinical Characteristics and Responses of Patients With Squamous-Cell Carcinoma of the Head and Neck Treated With mTOR Inhibitor-Based Regimens

Characteristic	Patient No.
	1	2	3	4	5
Age at treatment, years	16	56	73	49	59
Previous treatments	Surgery and neck dissection	Radiation	Subtotal glossectomy and bilateral dissection	Surgery; radiation	Radiation
	Chemoradiation with cisplatin	Interferon/vitamin E/13-cis-retinoic acid	Four therapeutic regimens including cisplatin, fluorouracil, docetaxel, cetuximab, everolimus, and erlotinib	Six therapeutic regimens including trastuzumab, cisplatin, paclitaxel, sorafenib, carboplatin, cixutumumab, and linsitinib	Two therapeutic regimens including: paclitaxel, carboplatin, brachytherapy, hyperthermia, cetuximab, docetaxel, cisplatin, and fluorouracil
	Carboplatin/docetaxel	Six therapeutic regimens including: cetuximab, carboplatin, paclitaxel, gemcitabine, docetaxel, and cetuximab	Radiation	Additional surgery	Additional radiation
	Additional surgeries		Additional surgeries		Surgeries
Disease site	Oral cavity	Tongue base	Tongue base	Oral tongue	Right tonsil
PIK3CA mutation	E542K	E542K	H1047R	No	No
PTEN	Present	Present	Not done	Absent	Absent
HPV Status	Negative	Negative	Negative	Negative	Positive
Treatment	Temsirolimus	Temsirolimus	Temsirolimus/bevacizumab	Temsirolimus/bevacizumab	Temsirolimus/bevacizumab
No. of treatment cycles	2	2	2	5	16
Time to tumor progression, months	1.5	1.5	1.5+*	3.3	11.5
Overall survival, months	2.9	1.5	1.5+*	5.1	15.5
Best RECIST response, %	20	25	−38	−24	−32

Abbreviations: HPV, human papillomavirus; mTOR, mammalian target of rapamycin; PTEN, phosphate and tensin homolog.

^*Patient stopped treatment after 1.5 months and had 38% tumor regression at that point. The patient did not return to follow-up with us to determine when his tumor began to progress, but we were informed of his date of death.